Effects of Intravenous Solanezumab 400 mg q 4 Weeks vs. Placebo on Biomarkers in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies (P01.011)
2013
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI